Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Clin Med Res ; 21(1): 36-45, 2023 03.
Article in English | MEDLINE | ID: covidwho-2313931

ABSTRACT

Cutaneous manifestations related to Coronavirus Disease-19 (COVID-19) have been reported over 2 years since the pandemic began. This research aimed to review articles published in English that describe cutaneous manifestations related to COVID-19/SARS-CoV-2. A data search for case reports, original studies, and review articles from the onset of the current COVID-19 pandemic to December 31, 2022, was performed using PUBMED, Cochrane Library, ResearchGate, and Google search engines. Keywords were "coronavirus", "novel coronavirus 2019", "COVID-19", "SARS-CoV-2", and "2019-nCoV" in combination with "cutaneous", "skin" and "dermatology" The extracted data included authors, region, sex, age, number of participants with skin signs, cutaneous signs, its location, symptoms, extracutaneous/associated symptoms, suspected or confirmed status for COVID-19, timeline, and healing duration. Six authors independently reviewed the abstracts and full-texts to identify publications providing these details concerning cutaneous manifestations related to COVID-19. A total of 139 publications with full text (122 case reports, 10 case series, and 7 review articles) that reported cutaneous manifestations were identified, and reviewed from 5 continents. The most common cutaneous manifestations of COVID-19 were maculopapular, followed by chilblain-like lesion, urticarial, livedoid/necrotic, vesicular, and other/non-descript rashes/skin lesions. After 2 years into the COVID-19 pandemic, we can conclude that there is no pathognomonic cutaneous manifestation of COVID-19, since it can be also found in other viral infections.


Subject(s)
COVID-19 , Skin Diseases , Humans , SARS-CoV-2 , Pandemics , Skin Diseases/diagnosis , Skin Diseases/etiology , COVID-19 Testing
2.
BMC Infect Dis ; 23(1): 7, 2023 Jan 06.
Article in English | MEDLINE | ID: covidwho-2196093

ABSTRACT

BACKGROUND: By August 2022, CoronaVirus Disease-2019 (COVID-19) had caused 600 million illnesses and 6.5 million fatalities globally. A massive vaccination program is being implemented worldwide to suppress this condition. Several works of literature stated that mRNA COVID-19 vaccination, specifically with the mRNA-1273 vaccine, is followed by clear evidence of the COVID arm effects associated with this vaccine. OBJECTIVE: To analyze the latest evidence of COVID arm as a common effect of mRNA-1273 vaccination with the ultimate goal of improving vaccine counseling to help healthcare professionals and reassure patients. METHODS: A comprehensive search was performed on topics that assess the COVID arm as a cutaneous manifestation following mRNA-1273 vaccination from inception up until July 2022. RESULTS: Eighteen studies with a total of 1129 participants after the first and second dose of mRNA-1273 vaccination reported that most participants had COVID arm following the first dose administration. The characteristics of the patients were a mean age of 43.8 years old, and females represented ≥ 50% in most studies, with a mean onset of 6.9 days after the first dose administration. Symptoms resolved within seven days following the treatment and were harmless. CONCLUSIONS: This study found that the COVID arm condition is most common following the first mRNA-1273 vaccination in the female and middle-aged group. The correlation between demographic variables and COVID arm risk elucidates that the reaction is a type IV allergic skin reaction.


Subject(s)
COVID-19 , Hypersensitivity, Delayed , Skin Diseases , Middle Aged , Humans , Female , Adult , 2019-nCoV Vaccine mRNA-1273 , Arm , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Vaccination/adverse effects
3.
Jurnal Arsitektur dan Perencanaan (JUARA) ; 4(2):100-111, 2021.
Article in Indonesian | Indonesian Research | ID: covidwho-1645569

ABSTRACT

Bencana dan pandemi memerlukan respon sistem kesehatan yang gesit. Karakter geografis Indonesia juga menuntut kelincahan di satu sisi dan integrasi sistem di sisi lain yang belum sepenuhnya direspons oleh sistem eksisting yang mengandalkan infrastruktur stasioner. Saat ini dalam literatur dan praktik global mobile health care system telah menjadi tren namun belum menjadi bagian dari wacana di Indonesia. Penelitian ini bertujuan untuk memulai desain rumah sakit modular untuk mengisi kesenjangan sistemik ini. Penelitian pendahuluan ini dilakukan dengan menggunakan metode tinjauan pustaka naratif untuk mengidentifikasi kriteria desain kritis sebagai bagian dari metodologi penelitian desain. Artikel ini merekomendasikan enam kriteria penting untuk ide desain arsitektur dan pengembangan kebijakan untuk rumah sakit mobile modular.

4.
BMJ Case Rep ; 13(10)2020 Oct 29.
Article in English | MEDLINE | ID: covidwho-894842

ABSTRACT

A 50-year-old man presented to our dermatology clinic with itchy skin rash. The rash began 5 days after systemic symptoms appeared such as mild fever and mild dyspnoea. The rashes were a characteristic of follicular eruption, which started on his stomach and spread all over his body. After a thorough evaluation, he was diagnosed with COVID-19 and was started on COVID-19 regimens. Skin lesions disappeared on the ninth day of treatment. Our findings contribute to the growing awareness of dermatological manifestations in patients with COVID-19.


Subject(s)
Coronavirus Infections/diagnosis , Exanthema/diagnosis , Pneumonia, Viral/diagnosis , Skin Diseases, Viral/diagnosis , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , COVID-19 , Coronavirus Infections/drug therapy , Diagnosis, Differential , Drug Therapy, Combination , Dyspnea/diagnosis , Dyspnea/etiology , Exanthema/drug therapy , Fever/diagnosis , Fever/etiology , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/drug therapy , Skin Diseases, Viral/drug therapy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL